Home › Non-Small Cell Lung Cancer › Massachusetts

Pag-aaral pangklinika para sa Non-Small Cell Lung Cancer sa Massachusetts

101 pag-aaral para sa Non-Small Cell Lung Cancer ang naghahanap ng mga kalahok sa mga site sa Massachusetts.

Mga Lungsod sa Massachusetts

Opisyal na teksto ng pag-aaral (English)

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Dana-Farber Cancer Institute, Boston

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT06765109

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Beverly Hospital, Beverly
Boston Medical Center, Boston
Beth Israel Deaconess Medical Center, Boston
at 8 pa

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT04267848

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Local Institution - 0603, Boston

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07361497

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

Massachusetts General Hospital, Boston

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07578571

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Dana-Farber Cancer Institute /ID# 278417, Boston

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT06772623

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Research Site, Boston
Research Site, Boston

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT05877599

A Study of PHN-012 in Patients With Advanced Solid Tumors

PHN-012-001 Site, Boston

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07127874

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Beverly Hospital, Beverly
Lahey Clinic, Burlington
Addison Gilbert Hospital, Gloucester
at 3 pa

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT06498635

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Massachusetts General Hospital ( Site 0136), Boston
Dana Farber Cancer Hospital ( Site 0155), Boston

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06623422

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

University of Massachusetts Worcester, Worcester

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07144280

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Boston Medical Center, Boston

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05498428

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Research Site, Boston

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06218914

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Southcoast Centers for Cancer Care, Fairhaven
Southcoast Centers for Cancer Care, Fall River

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06758401

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Reliant Medical Group Inc, Worcester

Nagre-recruitPhase 3

Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05920356

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Boston University Medical Center, Boston
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06667076

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

Beth Israel Deaconess Medical Center, Boston

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06667908

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Massachusetts General Hospital Cancer Center, Boston

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT03191149

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Lahey Hospital & Medical Center, Burlington
Reliant Medical Group, Worcester

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06890598

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Tufts Medical Center, Boston

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06047379

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site, Boston

Nagre-recruitPhase 2

Edad 18 hanggang 95 · Lahat ng kasarian · Na-update Set 23, 2026 · NCT05061550

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site, Boston
Research Site, Boston

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT06357533

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Dana Farber Cancer Institute, Boston

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06128551

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Dana-Farber Cancer Institute, Boston

Nagre-recruitPhase 2/3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07100080

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Local Institution - 0019, Boston

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06875310

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT05983432

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Massachusetts General Hospital - Main Campus, Boston

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT07629960

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Site, Boston
Clinical Study Site, Brighton
Clinical Study Site, Foxborough
at 4 pa

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT06767514

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

Dana-Farber Cancer Institute, Boston

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT06855771

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Dana-Farber Cancer Institute, Boston

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07349537

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Dana-Farber Cancer Institute, Boston

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07195695

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Dana-Farber Cancer Institute, Boston

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT05786924

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Dana-Farber Cancer Institute, Boston
Dana-Farber Cancer Institute at St. Elizabeths Medical Center, Brighton
Brigham and Womens/Mass General Health Care Center at Foxborough, Foxborough
at 3 pa

Nagre-recruitPhase 2/3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT04613596

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston

Nagre-recruitPhase 1/2

Edad 12 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT04585750

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Dana-Farber Cancer Institute, Boston

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT06899126

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Tufts, Boston
Dana-Farber Cancer Institute, Boston

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT06303505

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

Massachusetts General Hospital (Data Collection Only), Boston

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT04410796

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

Dana-Farber Cancer Institute, Boston

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 10, 2026 · NCT04302025

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

Massachusetts General Hospital - Neurology, Boston
Dana-Farber Cancer Institute - Oncology Department, Boston

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 10, 2026 · NCT06914128

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Massachusetts General Hospital, Boston
Dana-Farber Cancer Insitute, Boston

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06625775

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06253871

Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.